New diabetes drug tested in kidney patients: hope or hype?
NCT ID NCT01512849
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested an experimental diabetes drug called TA-7284 in 24 people with type 2 diabetes, some with normal kidneys and some with moderate kidney impairment. Researchers measured how the drug moves through the body, how it affects blood sugar, and whether it is safe. The goal is to understand if the drug works differently in patients with kidney problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TA-7284 (an experimental drug for type 2 diabetes)
What this could lead to
If successful, this could help determine the right dose of TA-7284 for diabetic patients with kidney problems, potentially leading to better blood sugar control.
What could go wrong
This is a very early Phase 1 study with only 24 participants, so results may not apply broadly. The drug may not work as expected or could cause side effects, especially in patients with kidney impairment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Kanto, Japan